

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* <b>BAUMGARTNER ROBERT V</b>			2. Issuer Name and Ticker or Trading Symbol <b>BIO-TECHNE Corp [TECH]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>08/23/2021</b>					
5775 WAYZATA BOULEVARD, SUITE 400								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
MINNEAPOLIS, MN 55416								
(City) (State) (Zip)			<b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/23/2021		M		4,000	A	\$ 87.39	13,612	D	
Common Stock	08/23/2021		S		299	D	\$ 481.774 (1)	13,313	D	
Common Stock	08/23/2021		S		601	D	\$ 483.5993 (2)	12,712	D	
Common Stock	08/23/2021		S		600	D	\$ 485.0254 (3)	12,112	D	
Common Stock	08/23/2021		S		1,600	D	\$ 486.2526 (4)	10,512	D	
Common Stock	08/23/2021		S		800	D	\$ 487.1027 (5)	9,712	D	
Common Stock	08/23/2021		S		100	D	\$ 487.8823 (6)	9,612	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$ 87.39	08/23/2021		M		4,000	10/31/2013	10/30/2023	Common Stock	4,000	\$ 0	0	D	

Stock Options (right to buy)	\$ 91.78							10/30/2014	10/30/2024	Common Stock	4,000		4,000	D	
Stock Options (right to buy)	\$ 87.34							10/29/2016	10/28/2025	Common Stock	4,260		4,260	D	
Stock Options (right to buy)	\$ 101.19							10/26/2017	10/26/2026	Common Stock	3,985		3,985	D	
Stock Options (right to buy)	\$ 125.05							10/25/2018	10/26/2027	Common Stock	3,125		3,125	D	
Stock Options (right to buy)	\$ 179.84							10/24/2019	10/25/2028	Common Stock	1,898		1,898	D	
Stock Options (right to buy)	\$ 201.64							10/24/2020	10/24/2029	Common Stock	2,011		2,011	D	
Stock Options (right to buy)	\$ 255.69							(7)	10/29/2030	Common Stock	1,507		1,507	D	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BAUMGARTNER ROBERT V 5775 WAYZATA BOULEVARD, SUITE 400 MINNEAPOLIS, MN 55416	X			

## Signatures

/s/ Brenda S. Furlow as Attorney-in-Fact for Robert V. Baumgartner pursuant to Power of Attorney previously filed.		08/25/2021
<small>**Signature of Reporting Person</small>		Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$481.41 to \$482.40, inclusive. The reporting person (1) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$483.01 to \$483.86, inclusive. The reporting person (2) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$484.52 to \$485.51, inclusive. The reporting person (3) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$485.59 to \$486.51, inclusive. The reporting person (4) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$486.84 to \$487.52, inclusive. The reporting person (5) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$487.87 to \$487.89, inclusive. The reporting person (6) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(7) The option vests on the earlier of the one year anniversary of the grant date (10/29/20) or the date of Bio-Techne's 2021 annual meeting of shareholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

